skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
HLA-A*0201-Restricted VEGFR1 Peptide Vaccine (Code C77878)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HLA-A*0201-Restricted VEGFR1 Peptide Vaccine

Definition: A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.

Label: HLA-A*0201-Restricted VEGFR1 Peptide Vaccine

NCI Thesaurus Code: C77878 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL387275  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A*0201-Restricted VEGFR1 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 597657
PDQ Open Trial Search ID 597657 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C77878
Legacy_Concept_Name HLA-A_0201-Restricted_VEGFR1_Peptide_Vaccine
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom